Lumibird SA - Asset Resilience Ratio
Lumibird SA (LBIRD) has an Asset Resilience Ratio of 22.85% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check LBIRD capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2024)
This chart shows how Lumibird SA's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Lumibird SA to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Lumibird SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Lumibird SA market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €45.19 Million | 10.37% |
| Short-term Investments | €54.43 Million | 12.49% |
| Total Liquid Assets | €99.62 Million | 22.85% |
Asset Resilience Insights
- Good Liquidity Position: Lumibird SA maintains a healthy 22.85% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Lumibird SA Industry Peers by Asset Resilience Ratio
Compare Lumibird SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cowealth Medical China Co.Ltd.
SHG:603122 |
Diagnostics & Research | 2.25% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
|
Cryosite Ltd
AU:CTE |
Diagnostics & Research | 5.65% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
Annual Asset Resilience Ratio for Lumibird SA (2000–2024)
The table below shows the annual Asset Resilience Ratio data for Lumibird SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 12.73% | €54.71 Million ≈ $63.97 Million |
€429.80 Million ≈ $502.48 Million |
+4.81pp |
| 2023-12-31 | 7.92% | €32.08 Million ≈ $37.51 Million |
€405.25 Million ≈ $473.78 Million |
+1.13pp |
| 2022-12-31 | 6.79% | €25.26 Million ≈ $29.53 Million |
€372.04 Million ≈ $434.96 Million |
+6.07pp |
| 2021-12-31 | 0.72% | €2.50 Million ≈ $2.93 Million |
€347.62 Million ≈ $406.41 Million |
+38.87pp |
| 2020-12-31 | -38.15% | €-116.51 Million ≈ $-136.22 Million |
€305.43 Million ≈ $357.08 Million |
-38.16pp |
| 2019-12-31 | 0.02% | €30.00K ≈ $35.07K |
€193.76 Million ≈ $226.52 Million |
-0.02pp |
| 2018-12-31 | 0.04% | €53.00K ≈ $61.96K |
€151.03 Million ≈ $176.58 Million |
-14.26pp |
| 2017-12-31 | 14.30% | €17.31 Million ≈ $20.24 Million |
€121.08 Million ≈ $141.55 Million |
+10.51pp |
| 2016-12-31 | 3.79% | €2.32 Million ≈ $2.71 Million |
€61.19 Million ≈ $71.54 Million |
+13.41pp |
| 2015-12-31 | -9.63% | €-5.88 Million ≈ $-6.88 Million |
€61.11 Million ≈ $71.44 Million |
-11.23pp |
| 2013-12-31 | 1.60% | €825.00K ≈ $964.51K |
€51.49 Million ≈ $60.20 Million |
+0.06pp |
| 2012-12-31 | 1.54% | €814.00K ≈ $951.65K |
€52.71 Million ≈ $61.62 Million |
+0.45pp |
| 2011-12-31 | 1.09% | €637.00K ≈ $744.72K |
€58.29 Million ≈ $68.15 Million |
+0.09pp |
| 2010-12-31 | 1.01% | €557.00K ≈ $651.19K |
€55.28 Million ≈ $64.63 Million |
+0.16pp |
| 2009-12-31 | 0.85% | €463.00K ≈ $541.30K |
€54.77 Million ≈ $64.03 Million |
+0.02pp |
| 2007-12-31 | 0.82% | €572.00K ≈ $668.73K |
€69.41 Million ≈ $81.14 Million |
+0.15pp |
| 2006-12-31 | 0.67% | €372.00K ≈ $434.91K |
€55.22 Million ≈ $64.56 Million |
-0.04pp |
| 2005-12-31 | 0.72% | €314.00K ≈ $367.10K |
€43.91 Million ≈ $51.34 Million |
+0.17pp |
| 2004-12-31 | 0.54% | €147.00K ≈ $171.86K |
€27.20 Million ≈ $31.80 Million |
-0.59pp |
| 2003-12-31 | 1.13% | €317.00K ≈ $370.61K |
€28.16 Million ≈ $32.92 Million |
+0.91pp |
| 2002-12-31 | 0.22% | €69.00K ≈ $80.67K |
€31.96 Million ≈ $37.37 Million |
+0.12pp |
| 2001-12-31 | 0.09% | €31.00K ≈ $36.24K |
€33.26 Million ≈ $38.88 Million |
-0.02pp |
| 2000-12-31 | 0.12% | €206.00K ≈ $240.84K |
€175.71 Million ≈ $205.42 Million |
-- |
About Lumibird SA
Lumibird SA designs, manufactures, and sells various lasers for scientific, industrial, and medical applications in France, Hong Kong, the United States, Germany, South Korea, China, and Austria. The company operates through Photonics and Medical divisions. It offers fiber lasers and amplifiers, high power fiber lasers, and solid-state lasers, laser diodes and components; and doppler wind LiDAR, … Read more